On Wednesday August 6, 2025, 11:00 AM ET , Thomas Heathman COO at Oribiotech, joined Keara Trinkle (Traylor), Director of Technical Solutions at Oribiotech, and Jeffrey Cram, Senior Director of Cellular Process Development, ElevateBiotools and services representatives on a panel discussion to explore their different approaches to scaling CGT manufacturing.
Accelerating Cell & Gene Therapy Scale-Up With An Advanced Manufacturing Platform.
Cell and gene therapy developers continue to face a critical challenge: how to scale manufacturing while maintaining product quality, consistency, and economic viability. Next-gen manufacturing technologies can offer a path forward, enabling higher yields, improved biological outcomes, and operational efficiencies that legacy systems struggle to deliver.
In this webinar, Ori Biotech and ElevateBio shared how an automated, scalable CGT platform was reshaping CGT manufacturing, supported by data demonstrating superior biological performance compared to legacy systems. Advanced platforms like IRO exemplified this shift by automating critical steps and integrating real-time monitoring while decreasing high production costs, variability in product quality, and the complexity of cell therapy manufacturing workflows.
By leveraging next-generation platforms, therapy developers were able to scale with confidence, ensuring quality and consistency from early-stage development through commercial manufacturing.
Key Learning Objectives
-
Learned how IRO improved biological performance, evaluating growth kinetics, transduction, metabolism, and phenotype throughout the expansion process vs. legacy systems
-
Leveraged the operational and economic benefits of adopting closed systems for faster clinical and commercial scale-up
-
Understood how early technology integration could accelerate scalable, quality-driven CGT manufacturing